Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02261116
Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02259803
Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 38
- Registration Number
- NCT02259816
Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02259829
Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02259790
Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population
- Conditions
- Interventions
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- The George Institute for Global Health, China
- Target Recruit Count
- 1410
- Registration Number
- NCT02255253
- Locations
- 🇨🇳
Chinese Traditional Medicine Hospital of Anguo, Baoding, Hebei, China
🇨🇳Lixian chinese traditional medicine hospital, Baoding, Hebei, China
🇨🇳People's hospital in Rongcheng, Baoding, Hebei, China
CKD-828 (80/5mg) Pharmacokinetic Study
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 69
- Registration Number
- NCT02250833
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, samdeok-dong, 2-ga 50, samdeok-dong, 2-ga 50 Jung-gu, Korea, Republic of
Antihypertensive Medications and the Risk of Sepsis
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1129062
- Registration Number
- NCT02248896
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13066
- Registration Number
- NCT02245464
A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5248
- Registration Number
- NCT02242396
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.